Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
In the stomach of a mummified wolf pup, scientists find DNA from a woolly rhinoceros - 2As tetanus vaccination rates decline, doctors worry about rising case numbers
- 3What's going on with Katseye? The Manon Bannerman hiatus drama, explained.
- 4Extreme Manual for Purchasing Your Next Truck
- 5Language Learning Applications for Voyagers
- Unraveling the Specialty of Picking Your Ideal Travel Objective
- UK can legally stop shadow fleet tankers, ministers believe
- Video Conferencing Instruments for Virtual Gatherings
- Shooting of MIT professor Nuno Loureiro has police searching for a suspect
- Portable Installment Answers for Independent ventures
- Historic underwater structure discovered by divers off French coast
- Getting ready for a Mechanized World: 10 Positions That computer based intelligence Could Dominate
- Potential Houthi threat to Red Sea shipping could further damage global economy
- The Way to Monetary Health: Individual budget Change
